MX2020003192A - Terapia de combinacion usando un antagonista del receptor de quimiocina tipo 2 (ccr2) y un inhibidor de pd-1/pd-l1. - Google Patents
Terapia de combinacion usando un antagonista del receptor de quimiocina tipo 2 (ccr2) y un inhibidor de pd-1/pd-l1.Info
- Publication number
- MX2020003192A MX2020003192A MX2020003192A MX2020003192A MX2020003192A MX 2020003192 A MX2020003192 A MX 2020003192A MX 2020003192 A MX2020003192 A MX 2020003192A MX 2020003192 A MX2020003192 A MX 2020003192A MX 2020003192 A MX2020003192 A MX 2020003192A
- Authority
- MX
- Mexico
- Prior art keywords
- ccr2
- antagonist
- inhibitor
- combination therapy
- chemokine receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente descripción lleva hacia la terapia de combinación de un antagonista del receptor de Quimiocina del Tipo 2 (CCR2) y un inhibidor de PD-1 y/o PD-L1 en el tratamiento del cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762562952P | 2017-09-25 | 2017-09-25 | |
PCT/US2018/052408 WO2019060820A1 (en) | 2017-09-25 | 2018-09-24 | POLYTHERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 / PD-L1 INHIBITOR |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003192A true MX2020003192A (es) | 2020-07-29 |
Family
ID=65810578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003192A MX2020003192A (es) | 2017-09-25 | 2018-09-24 | Terapia de combinacion usando un antagonista del receptor de quimiocina tipo 2 (ccr2) y un inhibidor de pd-1/pd-l1. |
Country Status (15)
Country | Link |
---|---|
US (2) | US11304952B2 (es) |
EP (1) | EP3687525A4 (es) |
JP (2) | JP7453139B2 (es) |
KR (1) | KR20200110300A (es) |
CN (1) | CN111712242B (es) |
AR (1) | AR112831A1 (es) |
AU (1) | AU2018335486A1 (es) |
BR (1) | BR112020005284A2 (es) |
CA (1) | CA3075638A1 (es) |
IL (1) | IL273188B2 (es) |
MA (1) | MA50665A (es) |
MX (1) | MX2020003192A (es) |
SG (1) | SG11202002119QA (es) |
TW (1) | TW201922287A (es) |
WO (1) | WO2019060820A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190275015A1 (en) * | 2017-09-25 | 2019-09-12 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
WO2019136368A2 (en) | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
MA51232A (fr) | 2018-02-22 | 2020-10-07 | Chemocentryx Inc | Indane-amines utiles en tant qu'antagonistes de pd-l1 |
WO2021007386A1 (en) | 2019-07-10 | 2021-01-14 | Chemocentryx, Inc. | Indanes as pd-l1 inhibitors |
BR112022006279A2 (pt) | 2019-10-16 | 2022-06-28 | Chemocentryx Inc | Heteroaril-bifenil aminas para o tratamento de doenças pd-l1 |
CN114907267A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 用于抗肿瘤的药物组合 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
DE69110787T2 (de) | 1990-02-28 | 1996-04-04 | Medtronic Inc | Intraluminale prothese mit wirkstoffeluierung. |
US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
AU2001273129A1 (en) | 2000-06-30 | 2002-01-14 | Bristol-Myers Squibb Pharma Company | N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
ATE337782T1 (de) | 2000-08-17 | 2006-09-15 | Merck & Co Inc | Cyclopentylmodulatoren der chemokin-rezeptor- aktivität |
BR0210733A (pt) | 2001-07-02 | 2004-07-20 | Astrazeneca Ab | Derivados de piperidina de utilidade úteis como moduladores da atividade do receptor de quimocina |
US20060030582A1 (en) | 2002-04-29 | 2006-02-09 | Demartino Julie | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
ATE404538T1 (de) | 2002-04-29 | 2008-08-15 | Merck & Co Inc | Tetrahydropyranylcyclopentyltetrahydroisochino- linmodulatoren der chemokinrezeptoraktivität |
JO2479B1 (en) | 2002-04-29 | 2009-01-20 | ميرك شارب اند دوم ليمتد | Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine |
SI1501507T1 (sl) | 2002-04-29 | 2008-12-31 | Merck & Co Inc | Tetrahidropiranil ciklopentil tetrahidropiridopiridin modulatorji s kemokinsko receptorsko aktivnostjo |
EP1558599A4 (en) | 2002-10-30 | 2007-06-27 | Merck & Co Inc | HETEROARYLPIPERIDINE MODULATORS DERCHEMOKIN RECEPTORACTIVITY |
EP1599206A4 (en) | 2003-02-24 | 2008-05-21 | Merck & Co Inc | MODULATORS OF HETEROTRICYLICAMIDE FUSIONED WITH AMINOCYCLOPENTYL OF ACTIVITY OF CHEMOKINE RECEPTORS |
US7553841B2 (en) | 2003-03-18 | 2009-06-30 | Merck & Co., Inc. | Amino cyclobutylamide modulators of chemokine receptor activity |
KR20060003353A (ko) | 2003-04-15 | 2006-01-10 | 머크 앤드 캄파니 인코포레이티드 | 케모킨 수용체의벤족사지닐-아미도사이클로펜틸-헤테로사이클릭 조절제 |
AU2004232939A1 (en) | 2003-04-17 | 2004-11-04 | Merck Sharp & Dohme Corp. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
US20060205761A1 (en) | 2003-06-06 | 2006-09-14 | Catherine Abbadie | Ccr-2 antagonists for treatment of neuropathic pain |
AU2004287416C1 (en) | 2003-10-27 | 2010-09-09 | Merck Sharp & Dohme Corp. | CCR-2 antagonist salt |
AR045875A1 (es) | 2003-10-27 | 2005-11-16 | Merck & Co Inc | Procedimiento para la preparacion del antagonista ccr-2 |
US20070117797A1 (en) | 2004-01-02 | 2007-05-24 | Goble Stephen D | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity |
EP1716134A4 (en) | 2004-02-12 | 2007-10-17 | Merck & Co Inc | AMINO HETEROCYCLIC COMPOUNDS MODULATING CHEMOKINE RECEPTOR ACTIVITY |
GEP20084519B (en) | 2004-05-11 | 2008-10-27 | Incyte Corp | 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors |
PA8653301A1 (es) | 2004-11-22 | 2006-11-09 | Incyte Corp Incyte Corp | Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin |
JP2008526861A (ja) | 2005-01-06 | 2008-07-24 | メルク エンド カムパニー インコーポレーテッド | 炎症性障害を治療するための薬剤併用療法および医薬組成物 |
US8519135B2 (en) | 2006-07-14 | 2013-08-27 | Chemocentryx, Inc. | Heteroaryl sulfonamides and CCR2/CCR9 |
US7671062B2 (en) | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
KR101849560B1 (ko) | 2007-07-12 | 2018-04-17 | 케모센트릭스, 인크. | 염증의 치료를 위한 ccr2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
CN102264762B (zh) | 2008-09-26 | 2018-03-27 | 达纳-法伯癌症研究公司 | 人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用 |
JP5782381B2 (ja) | 2008-12-10 | 2015-09-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | Ccr2の4−アゼチジニル−1−ヘテロアリール−シクロヘキサノールアンタゴニスト |
EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
BRPI1016207A2 (pt) | 2009-04-16 | 2016-04-26 | Janssen Pharmaceutica Nv | compostos de 4-azetidinil-1-heteroaril-ciclohexano antagonistas de ccr2 |
WO2010121046A1 (en) | 2009-04-17 | 2010-10-21 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
ES2524829T3 (es) | 2009-12-17 | 2014-12-12 | Boehringer Ingelheim International Gmbh | Nuevos antagonistas del receptor CCR2 y usos de los mismos |
ES2449379T3 (es) | 2010-02-09 | 2014-03-19 | Bristol-Myers Squibb Company | Derivados de bencilpirrolidinona como moduladores de la actividad de receptores de quimiocinas |
JP2013526507A (ja) | 2010-05-12 | 2013-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ccr2受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
EP2582692B1 (en) | 2010-06-17 | 2015-07-22 | Janssen Pharmaceutica NV | Cyclohexyl-azetidinyl antagonists of ccr2 |
WO2012121361A1 (ja) | 2011-03-10 | 2012-09-13 | 第一三共株式会社 | ジスピロピロリジン誘導体 |
BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
US8822460B2 (en) | 2012-04-06 | 2014-09-02 | Janssen Pharmaceutica Nv | Fused cyclopentyl antagonists of CCR2 |
US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
AU2013267267B2 (en) | 2012-05-31 | 2017-10-26 | Genentech, Inc. | Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists |
EP2864358B1 (en) | 2012-06-22 | 2019-08-07 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind ccr2 |
US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
WO2015002754A2 (en) | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Corp. | Novel bicyclic bromodomain inhibitors |
RU2705795C2 (ru) | 2013-08-20 | 2019-11-12 | Мерк Шарп И Доум Корп. | Лечение рака комбинацией антагониста pd-1 и динациклиба |
AU2014315457B2 (en) | 2013-09-04 | 2018-05-10 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
EP3191113B1 (en) | 2014-09-11 | 2019-11-06 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-l1 protein/protein interactions |
US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
BR112017024555A2 (pt) | 2015-05-21 | 2018-07-24 | Chemocentryx Inc | moduladores de ccr2 |
WO2017165125A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
CN109803651B (zh) | 2016-06-27 | 2022-05-31 | 凯莫森特里克斯股份有限公司 | 免疫调节剂化合物 |
JP2020517256A (ja) * | 2017-04-19 | 2020-06-18 | エルスター セラピューティクス, インコーポレイテッド | 多重特異性分子およびその使用 |
US20190275015A1 (en) | 2017-09-25 | 2019-09-12 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor |
US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
WO2019136368A2 (en) | 2018-01-08 | 2019-07-11 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
BR112020014574A2 (pt) * | 2018-01-22 | 2020-12-08 | Bristol-Myers Squibb Company | Composições e métodos para o tratamento do câncer |
US20200297708A1 (en) | 2019-03-19 | 2020-09-24 | Chemocentryx, Inc. | Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1 and/or PD-L1 Inhibitor |
-
2018
- 2018-09-24 CN CN201880062100.3A patent/CN111712242B/zh active Active
- 2018-09-24 JP JP2020516857A patent/JP7453139B2/ja active Active
- 2018-09-24 CA CA3075638A patent/CA3075638A1/en active Pending
- 2018-09-24 IL IL273188A patent/IL273188B2/en unknown
- 2018-09-24 SG SG11202002119QA patent/SG11202002119QA/en unknown
- 2018-09-24 AU AU2018335486A patent/AU2018335486A1/en active Pending
- 2018-09-24 WO PCT/US2018/052408 patent/WO2019060820A1/en unknown
- 2018-09-24 EP EP18857688.8A patent/EP3687525A4/en active Pending
- 2018-09-24 US US16/139,745 patent/US11304952B2/en active Active
- 2018-09-24 BR BR112020005284-1A patent/BR112020005284A2/pt unknown
- 2018-09-24 MA MA050665A patent/MA50665A/fr unknown
- 2018-09-24 AR ARP180102736A patent/AR112831A1/es unknown
- 2018-09-24 KR KR1020207011664A patent/KR20200110300A/ko not_active Application Discontinuation
- 2018-09-24 MX MX2020003192A patent/MX2020003192A/es unknown
- 2018-09-25 TW TW107133664A patent/TW201922287A/zh unknown
-
2022
- 2022-03-15 US US17/694,829 patent/US20230023075A1/en active Pending
-
2023
- 2023-09-28 JP JP2023168563A patent/JP2023181168A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2020535144A (ja) | 2020-12-03 |
CN111712242B (zh) | 2023-11-24 |
US20190134049A1 (en) | 2019-05-09 |
AU2018335486A1 (en) | 2020-03-26 |
RU2020112755A3 (es) | 2022-03-31 |
IL273188B2 (en) | 2023-03-01 |
AR112831A1 (es) | 2019-12-18 |
RU2020112755A (ru) | 2021-10-28 |
US20230023075A1 (en) | 2023-01-26 |
SG11202002119QA (en) | 2020-04-29 |
BR112020005284A2 (pt) | 2020-09-24 |
EP3687525A4 (en) | 2021-10-13 |
EP3687525A1 (en) | 2020-08-05 |
WO2019060820A1 (en) | 2019-03-28 |
US11304952B2 (en) | 2022-04-19 |
IL273188B (en) | 2022-11-01 |
KR20200110300A (ko) | 2020-09-23 |
IL273188A (en) | 2020-04-30 |
JP2023181168A (ja) | 2023-12-21 |
JP7453139B2 (ja) | 2024-03-19 |
MA50665A (fr) | 2020-08-05 |
CN111712242A (zh) | 2020-09-25 |
CA3075638A1 (en) | 2019-03-28 |
TW201922287A (zh) | 2019-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003192A (es) | Terapia de combinacion usando un antagonista del receptor de quimiocina tipo 2 (ccr2) y un inhibidor de pd-1/pd-l1. | |
PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
ZA202007007B (en) | Mcl-1 inhibitors | |
CR20190478A (es) | Inhibidores de pd-1/pd-l1 | |
PH12020550400A1 (en) | Combination therapies and uses thereof | |
PH12020550936A1 (en) | Combination drug including tlr7 agonist | |
PH12017500994A1 (en) | Anti-pd-1 antibodies and methods of use thereof | |
MX2019003780A (es) | Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres. | |
MX2016002273A (es) | Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib. | |
MX2019007243A (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
MX2020013808A (es) | Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer. | |
MX2017010595A (es) | Métodos, composiciones, y equipos para tratamiento de cáncer. | |
PH12020550079A1 (en) | Rad51 inhibitors | |
MX2020013320A (es) | Inhibidores de ectonucleotidasa y métodos de uso de los mismos. | |
MX2018004132A (es) | Método de tratamiento de meduloblastoma con un inhibidor de ezh2. | |
MX2021011689A (es) | Combinaciones de inhibidores de rad51 y parp. | |
MX2023010501A (es) | Profarmacos de dantroleno y metodos de su uso. | |
MX2019013862A (es) | Terapia de combinacion. | |
PH12017501980A1 (en) | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) | |
PH12020500400A1 (en) | Il-33 antagonist-containing therapeutic agent for endometriosis | |
MX2022006932A (es) | Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control. | |
MX2021015628A (es) | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso. | |
MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
MX2021002302A (es) | Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control. |